Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Next Previous
Trial Profile

A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INB-400 (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors IN8bio

Most Recent Events

  • 06 Nov 2025 According to an IN8bio media release, updated INB-200 clinical results in newly diagnosed glioblastoma (GBM) will be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, , November 19-23, 2025
  • 02 Jun 2025 According an IN8bio media release, additional updates expected late 2025
  • 13 Mar 2025 According an IN8bio media release, company has paused enrollment in the Phase 2 INB-400 glioblastoma program despite compelling data, to focus resources while exploring partnership and alternative funding opportunities.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top